NuVasive, Inc. (NUVA) News

NuVasive, Inc. (NUVA): $64.85

0.70 (+1.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NUVA News Items

NUVA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NUVA News Highlights

  • 500 - Internal server error
  • Over the past 23 days, the trend for NUVA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about NUVA are CE, AGE and AMS.

Latest NUVA News From Around the Web

Below are the latest news stories about Nuvasive Inc that investors may wish to consider to help them evaluate NUVA as an investment opportunity.

NuVasive (NUVA) Launches Modulus ALIF for Anterior Spine Surgery

The Modulus ALIF 3D-printed porous titanium implant is the latest addition to NuVasive's (NUVA) AMS portfolio for anterior lumbar interbody fusion procedures.

Yahoo | July 23, 2021

NuVasive's (NASDAQ:NUVA) Returns On Capital Not Reflecting Well On The Business

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...

Yahoo | July 23, 2021

NuVasive Launches Modulus ALIF 3D-Printed Porous Titanium Implant for Anterior Spine Surgery

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Modulus® ALIF, a 3D-printed porous titanium implant for anterior lumbar interbody fusion (ALIF), in targeted global regions.

Yahoo | July 22, 2021

Hedge Funds Are Souring On NuVasive, Inc. (NUVA)

In this article we will check out the progression of hedge fund sentiment towards NuVasive, Inc. (NASDAQ:NUVA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]

Yahoo | July 22, 2021

NuVasive (NUVA) Earnings Expected to Grow: Should You Buy?

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 21, 2021

NuVasive Announces Conference Call and Webcast of Second Quarter 2021 Results

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter 2021 earnings results on Wednesday, July 28, 2021, after the close of the market.

Yahoo | July 14, 2021

NuVasive (NUVA) International Sales Solid Despite COVID-19 Woes

We are upbeat about NuVasive's (NUVA) newly-introduced organizational and leadership structure for its global commercial operations as well as its product and services organization.

Yahoo | July 13, 2021

FDA Flags Certain Biocompatibility Concerns For NuVasive's Orthopedics' Precice Devices

The FDA informed healthcare providers of potential biocompatibility concerns with NuVasive Inc's (NASDAQ: NUVA) specialized orthopedics' Precice devices. Precice devices are implants for 18 years of age and older and are used to lengthen the limb, shorten or compress the limb, or transport segments of long bones. They include adjustable rods that are placed inside a patient and are driven by an internal magnetic mechanism. According to an FDA notice, there have been reports describing pain and c

Yahoo | July 9, 2021

NuVasive receives CE mark approval for Pulse platform

NuVasive (NUVA) announces that the Pulse platform received CE Mark approval for its latest design update; clinical evaluations are underway in multiple countries throughout Europe. "There is a substantial opportunity for enabling technology adoption in spine surgery, and we are leveraging our expertise in proceduralization to introduce Pulse. This next...

Seeking Alpha | June 30, 2021

NuVasive’s Pulse Platform Bags CE Mark Approval for Latest Design Update

NuVasive (NUVA) has announced that its Pulse platform has received CE Mark approval for the latest design update, and clinical evaluations are underway in multiple countries throughout Europe. The approval is considered a key commercialization milestone, expected to pave the way for the company’s expanded global launch this year. With this approved technology, several tools such as radiation reduction, imaging enhancement, rod bending, navigation, intraoperative neuromonitoring, and spinal alignment can be integrated into one platform. Notably, Pulse is expected to increase safety, efficiency, and procedural reproducibility.

Radhika Saraogi on TipRanks | June 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6716 seconds.